Beta Bionics (NASDAQ:BBNX) Raised to Hold at Wall Street Zen

Beta Bionics (NASDAQ:BBNX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other analysts have also recently weighed in on BBNX. Robert W. Baird cut their price target on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 18th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $25.00 price objective on shares of Beta Bionics in a research report on Thursday, January 15th. Bank of America downgraded Beta Bionics from a “buy” rating to a “neutral” rating in a report on Friday, January 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Beta Bionics in a research report on Monday, December 29th. Finally, Stifel Nicolaus decreased their target price on Beta Bionics from $25.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Beta Bionics has a consensus rating of “Moderate Buy” and an average price target of $23.20.

Beta Bionics Stock Down 0.7%

NASDAQ BBNX opened at $10.73 on Friday. Beta Bionics has a 52 week low of $8.89 and a 52 week high of $32.71. The stock has a market capitalization of $475.98 million, a PE ratio of -5.50 and a beta of 5.60. The firm has a 50 day moving average of $13.70 and a two-hundred day moving average of $21.74.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.12. The business had revenue of $32.12 million for the quarter. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%.

Insider Buying and Selling at Beta Bionics

In related news, insider Mike Mensinger sold 2,200 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total value of $66,220.00. Following the completion of the sale, the insider directly owned 80,752 shares of the company’s stock, valued at $2,430,635.20. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the transaction, the chief financial officer owned 42,614 shares of the company’s stock, valued at $1,258,391.42. This represents a 31.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 34,705 shares of company stock worth $945,653 over the last quarter.

Institutional Trading of Beta Bionics

A number of large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd grew its stake in Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after buying an additional 1,818 shares during the last quarter. Invesco Ltd. lifted its stake in Beta Bionics by 140.9% in the fourth quarter. Invesco Ltd. now owns 117,360 shares of the company’s stock valued at $3,576,000 after buying an additional 68,640 shares during the last quarter. XTX Topco Ltd purchased a new stake in Beta Bionics in the fourth quarter valued at approximately $1,340,000. Voloridge Investment Management LLC boosted its holdings in shares of Beta Bionics by 549.6% in the fourth quarter. Voloridge Investment Management LLC now owns 151,647 shares of the company’s stock valued at $4,621,000 after acquiring an additional 128,301 shares during the period. Finally, Tudor Investment Corp ET AL grew its position in shares of Beta Bionics by 572.7% during the fourth quarter. Tudor Investment Corp ET AL now owns 259,632 shares of the company’s stock worth $7,911,000 after acquiring an additional 221,039 shares during the last quarter.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.